Search

everythinglearnresearchcommunity

for

Search:↓

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Gefitinib can cause hair and eyebrow darkening.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Gefitinib can cause rare scarring hair loss.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Nilotinib can cause keratosis pilaris, a skin condition.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib might be used to treat hair loss.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Gefitinib can cause hair loss without scarring.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Gefitinib therapy can cause unusual hair growth on the nose.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.